ReviewBritish journal of pharmacology2020
A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019.
Review in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 39 citations in OpenAlex.
- Modulation of immune responses by opioids through toll-like and P2X receptor signaling in COVID-19.Purinergic signalling · 2026Review
- Treatment with intravenous immunoglobulin modulates coagulation- and complement-related pathways in COVID-19 patients.Frontiers in immunology · 2025Article
- Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.International journal of molecular sciences · 2024Review
- Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.International journal of molecular sciences · 2024Review
- Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer.Medical oncology (Northwood, London, England) · 2023Review
- COVID-19 triggers attacks in HAE patients without worsening disease outcome.The journal of allergy and clinical immunology. In practice · 2022Article
- Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Therapeutics for COVID-19 and post COVID-19 complications: An update.Current research in pharmacology and drug discovery · 2022Review
- Vanadium as potential therapeutic agent for COVID-19: A focus on its antiviral, antiinflamatory, and antihyperglycemic effects.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022Review
- Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19.Mediators of inflammation · 2022Review
- A proteomic survival predictor for COVID-19 patients in intensive care.PLOS digital health · 2022Article
- Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study.Frontiers in immunology · 2022Article
- How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment.Frontiers in immunology · 2022Review
- Activation of the AIM2 Receptor in Circulating Cells of Post-COVID-19 Patients With Signs of Lung Fibrosis Is Associated With the Release of IL-1α, IFN-α and TGF-β.Frontiers in immunology · 2022Article
- Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β.Biomedicines · 2021Article
- WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation -The World Allergy Organization journal · 2021Review
- Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19.Free radical biology & medicine · 2021Review
- COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications.Allergy and asthma proceedings · 2021Article
- Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID.International journal of molecular sciences · 2021Review
- COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.Molecular biology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The newly identified coronavirus SARS-CoV-2 that spread from China is causing the pandemic COVID-19 with a fatality rate from 5-15%. It causes fever, cough, myalgia, fatigue up to dyspnoea, responsible for hospitalization and artificial oxygenation. SARS-CoV-2 infects human cells using ACE2, the transmembrane protease serine 2 (TMPRSS2) and the SARS-CoV-2 main protease (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.